Skip to main content

Alcohol Use clinical trials at UCSF
11 in progress, 6 open to new patients

  • A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD

    open to eligible people ages 18-65

    The goal of this project is to improve the treatment of veterans with co-occurring alcohol dependence and posttraumatic stress disorder (PTSD). The PI and co-investigators will conduct a controlled clinical trial of topiramate for the treatment of these co-occurring disorders.

    San Francisco, California

  • Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

    open to eligible males ages 21-50

    The overall goal of the proposed project is to improve the treatment of individuals with AUD. We will conduct the first pilot human laboratory study to assess the effects of two doses of lacosamide on alcohol drinking and craving. We will assess its effects on reducing alcohol intake using a human laboratory method, the Yale Alcohol Drinking Paradigm (ADP). We will also assess the feasibility of the Alcohol Drinking Paradigm (ADP) in order to position our research team to have the capacity to conduct future, larger, hypothesis-testing human laboratory-based experiments designed to test the efficacy of potential alcohol treatments.

    San Francisco, California

  • Pilot Human Laboratory Study of Alcohol Approach Bias Modification (AABM) for AUD

    open to eligible males ages 21-50

    The overall goal of the proposed project is to improve the treatment of individuals with Alcohol Use Disorder (AUD). We will conduct a pilot feasibility trial of Approach Bias Modification (AABM) training of heavy-drinking non-treatment seeking individuals with AUD. We will measure feasibility with respect to recruitment, retention and tolerability of AABM training and the Alcohol Drinking Paradigm (ADP). We will also assess changes in alcohol craving and alcohol consumption during ADP sessions conducted before and after 3 weeks of AABM or sham training.

    San Francisco, California

  • Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM

    open to eligible males ages 18-70

    This is a double-blind, placebo-controlled trial of 120 binge-drinking MSM to 12 weeks of naltrexone 50mg, to be taken in anticipation of heavy drinking. Ethnically and racially diverse participants will be recruited using Respondent Driven Sampling as well as active field recruitment. MSM will be seen weekly for alcohol-metabolite urine testing, study drug dispensing, and brief counseling for alcohol use. Safety assessments and behavioral surveys will be completed monthly.

    San Francisco, California

  • The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study

    open to eligible people ages 21-81

    Atrial fibrillation (AF) is the most common sustained arrhythmia in the United States and it has been associated with ethanol use. Understanding how ethanol affects the electrical properties of the heart and induces AF has important public health implications. The objective of this research is to investigate the mechanistic relationship between ethanol and atrial fibrillation in humans by performing a placebo controlled study looking at the electrical properties of the heart in patients receiving intravenous ethanol or placebo. The investigators hypothesize that ethanol increases the susceptibility of human myocardium to atrial fibrillation through electrophysiologic changes in the atrial myocardium in the acute setting.

    San Francisco, California

  • Virtual Reality- Working Memory Retraining

    open to eligible people ages 18-65

    This study will establish the acceptability and feasibility of enrolling and retaining heavy drinking Veterans with mild traumatic brain injury (mTBI) in an 8-week, randomized cross-over design trial of active VR working memory retraining (WMR). This study will also seek to establish the efficacy of active VR-WMR to increase performance in executive function.

    San Francisco, California

  • Addressing Heavy Alcohol Use Consumption With Kudzu

    Sorry, not yet accepting patients

    Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol use and alcohol-associated sexual behaviors among sexually-active, binge-drinking individuals at high risk for HIV infection.

  • Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

    Sorry, not currently recruiting here

    The purpose of this study is to determine the effects of tolcapone on decision making and alcohol intake using a laboratory bar (on-site alcohol self-administration) in alcohol drinkers.

    San Francisco, California and other locations

  • Oxytocin on Approach Bias and Craving

    Sorry, not yet accepting patients

    This will be a laboratory-based investigation of the behavioral and neural effects of intranasal oxytocin on craving for alcohol and approach bias in moderate to heavy alcohol using subjects. This study uses a within-subject, randomized, placebo-controlled, counterbalanced, crossover design to compare the effects oxytocin and placebo. In this way, all subjects will be scanned twice; once following oxytocin administration and once following placebo administration, and will complete a series of behavioral tasks (both in and out of the scanner) at both visits.

    Berkeley, California

  • Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

    Sorry, in progress, not accepting new patients

    This component of a larger Center of Research Excellence Grant improves treatment for drug abuse by developing effective linkages between specialty drug treatment and primary health care.

    San Francisco, California

  • Smoking Tobacco and Drinking Study

    Sorry, in progress, not accepting new patients

    This trial will test the efficacy of a 3-month intervention on Facebook targeting tobacco use and heavy episodic drinking against a 3-month Facebook intervention targeting tobacco use. Both groups will be offered a nicotine patch starter kit. The primary outcome is verified 7-day point prevalence abstinence from smoking at 3, 6, and 12 months.

    San Francisco, California

Last updated: